A review of trabectedin (ET-743): a unique mechanism of action

Molecular Cancer Therapeutics
Maurizio D'Incalci, Carlos María Galmarini

Abstract

Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. Two of these rings (subunits A and B) provide the framework for covalent interaction with the minor groove of the DNA double helix, whereas the third ring (subunit C) protrudes from the DNA duplex, apparently allowing interactions with adjacent nuclear proteins. The compound's chemical interactions trigger a cascade of events that interfere with several transcription factors, DNA binding proteins, and DNA repair pathways, likely to be different from other DNA-interacting agents. Trabectedin also causes modulation of the production of cytokines and chemokines by tumor and normal cells, suggesting that the antitumor activity could also be ascribed to changes in the tumor microenvironment. The promising data on the combination of trabectedin with other anticancer agents, observed in preclinical systems, have prompted several clinical studies that are currently ongoing. One of these combinations (trabectedin-pegylated liposomal doxorubicin) was recently authorized by the European Commission for the treatment of patients with relapsed platinum-sen...Continue Reading

References

Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·S JinK W Scotto
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·M MinuzzoR Mantovani
Feb 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E ErbaM D'Incalci
Apr 17, 2001·International Journal of Cancer. Journal International Du Cancer·G DamiaM D'Incalci
Jan 5, 2002·Advances in Experimental Medicine and Biology·L H Hurley, M Zewail-Foote
Aug 13, 2002·Anti-cancer Drugs·Gregory J AuneYves Pommier
Jun 5, 2003·Cancer Chemotherapy and Pharmacology·Daniela MecoRiccardo Riccardi
Aug 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M D'IncalciG T Faircloth
Nov 26, 2003·Biochemical Pharmacology·Li ShaoLawrence Weissbach
Nov 6, 2004·Cancer Genetics and Cytogenetics·Avery A Sandberg
Jan 22, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S MarchiniM D'Incalci
Jun 18, 2005·Molecular Pharmacology·Mario MinuzzoRoberto Mantovani
Jun 26, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giovanna Damia, Maurizio D'Incalci
Jul 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Daniele Grazziotin SoaresAnnette K Larsen
Feb 5, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M TavecchioG Damia
May 17, 2008·Molecular Cancer Therapeutics·José A CasadoJuan A Bueren
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory J AuneYves Pommier
Feb 5, 2009·Molecular Cancer Therapeutics·Claudia ForniRoberto Mantovani
Feb 26, 2009·Natural Product Reports·Carmen Cuevas, Andrés Francesch
May 26, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F GrossoP G Casali
Mar 11, 2010·Cancer Research·Giovanni GermanoPaola Allavena

❮ Previous
Next ❯

Citations

Sep 4, 2013·Journal of Industrial Microbiology & Biotechnology·Lesley-Ann Giddings, David J Newman
Apr 28, 2011·Current Oncology Reports·Jason L Smith, Richard F Riedel
Jun 3, 2011·Current Oncology Reports·Sherif S Morgan, Lee D Cranmer
Jun 10, 2011·Journal of Natural Products·A Douglas KinghornHeebyung Chai
Nov 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Sessa, M D'Incalci
Jun 7, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GronchiJ Y Blay
Jul 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J SehouliA González-Martín
Sep 21, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D MichaelsonM R Smith
Feb 2, 2012·The Journal of Clinical Investigation·Elizabeth CharytonowiczIgor Matushansky
Oct 15, 2011·Immunotherapy·Chiara PortaAlberto Mantovani
Apr 19, 2011·Clinical Medicine Insights. Oncology·Csaba Gajdos, Anthony Elias
Sep 3, 2011·Future Medicinal Chemistry·Rana Montaser, Hendrik Luesch
Jan 30, 2014·Marine Drugs·Carlos M GalmariniPaola Allavena
Feb 13, 2013·Case Reports in Oncological Medicine·Markus K SchulerGerhard Ehninger
Nov 15, 2013·Future Oncology·Maurizio D'Incalci
Apr 3, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DelalogeJ Lubinski
Jun 21, 2014·Future Oncology·Mark R KelleyMelissa L Fishel
Apr 24, 2014·British Journal of Cancer·M D'IncalciP Allavena
Jul 23, 2014·Future Oncology·Thomas Brodowicz
Dec 18, 2013·Immunology Letters·Diana Boraschi, Giselle Penton-Rol
Sep 12, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christian LeporiniEmilio Russo
Nov 12, 2013·Oncogene·S Di GiandomenicoM D'Incalci
Jan 24, 2014·Future Oncology·Ioannis GounarisHelena M Earl
Feb 5, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Nobuhito ArakiAkira Kawai
Jan 26, 2016·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Rolf IsselsLars H Lindner
Jul 18, 2015·International Journal of Molecular Sciences·Emanuele-Salvatore Scarpa, Paolino Ninfali
Feb 17, 2015·Marine Drugs·Bradley J PetekRobin L Jones
Dec 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Angela Cioffi, Antoine Italiano
Aug 14, 2013·Expert Opinion on Drug Safety·Juan Martin-Liberal, Ian Judson
Nov 26, 2015·Expert Opinion on Investigational Drugs·Maurizio D'Incalci, Alberto Zambelli
Dec 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LorussoG Ferrandina
Nov 15, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Daniela D'AngeloAlfredo Fusco
Apr 17, 2012·Current Opinion in Pharmacology·John A Hartley, Daniel Hochhauser

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.